Literature DB >> 2665798

Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity.

R Holmdahl1, M E Andersson, T J Goldschmidt, L Jansson, M Karlsson, V Malmström, J Mo.   

Abstract

The type II collagen (CII) induced arthritis animal model (CIA) provides opportunities to study the nature of autoimmune reactions leading to arthritis and may be used as a model for rheumatoid arthritis (RA). Thus, in similarity with RA, the CIA model, when induced with autologous CII, shows a chronic and progressive disease course. The susceptibility to both RA and CIA are correlated to the expression of certain MHC class II allotype genes. In both diseases are autoantibodies to CII and rheumatoid factors produced. Immunohistopathology of affected joints show in both diseases a dominance of activated macrophages/fibroblasts with a significant infiltration of activated T cells and an infiltration of granulocytes. We do here suggest that both RA and CIA are dependent on a synergy between delayed type hypersensitivity and immune complex mediated inflammatory mechanisms and that CIA provides opportunities for studies of immunospecific reactions leading to arthritis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665798     DOI: 10.1111/j.1699-0463.1989.tb00446.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  33 in total

Review 1.  Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 2.  Analysing the effect of novel therapies on cytokine expression in experimental arthritis.

Authors:  Richard O Williams; Julia J Inglis; Egle Simelyte; Gabriel Criado; Percy F Sumariwalla
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

Review 3.  Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?

Authors:  R O Williams
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Adhesion molecules in inflammatory diseases: insights from knockout mice.

Authors:  Daniel C Bullard
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  Critical role of M. tuberculosis for dendritic cell maturation to induce collagen-induced arthritis in H-2b background of C57BL/6 mice.

Authors:  Hirayasu Kai; Kazuko Shibuya; Yinan Wang; Hirotaka Kameta; Tomie Kameyama; Satoko Tahara-Hanaoka; Akitomo Miyamoto; Shin-ichiro Honda; Isao Matsumoto; Akio Koyama; Takayuki Sumida; Akira Shibuya
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

6.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.

Authors:  T Shouda; T Yoshida; T Hanada; T Wakioka; M Oishi; K Miyoshi; S Komiya; K Kosai; Y Hanakawa; K Hashimoto; K Nagata; A Yoshimura
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

7.  Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice.

Authors:  Y Fujimori; T Nakamura; K Shimizu; T Yamamuro; K Wanaka; S Okamoto; Y Katsuura
Journal:  Agents Actions       Date:  1993-05

Review 8.  Possible roles of IL-12-family cytokines in rheumatoid arthritis.

Authors:  Richard M Pope; Shiva Shahrara
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

9.  CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis.

Authors:  Zhongyu Liu; Xin Xu; Hui-Chen Hsu; Albert Tousson; Ping-Ar Yang; Qi Wu; Cunren Liu; Shaohua Yu; Huang-Ge Zhang; John D Mountz
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

10.  Antibody targeting of TIRC7 results in significant therapeutic effects on collagen-induced arthritis in mice.

Authors:  N Utku; T Heinemann; M Winter; C G Bulwin; M Schlawinsky; P Fraser; E E S Nieuwenhuis; H-D Volk; R S Blumberg
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.